{ "schemaVersion": 2, "eyebrow": "Pulmonology", "title": "Interstitial Lung Disease", "summary": "Interstitial lung disease requires early separation of infection, drug toxicity, exposure-related disease, autoimmune ILD, and idiopathic pulmonary fibrosis through high-resolution CT, pulmonary function testing, exposure history, serology, and multidisciplinary review to direct treatment and monitor progression.", "seoDescription": "A physician-focused approach to interstitial lung disease using HRCT patterns, pulmonary function trends, multidisciplinary diagnosis, and progression assessment.", "clinicalQuestion": "How should clinicians evaluate, classify, monitor, and escalate care for suspected fibrotic interstitial lung disease?", "specialty": "Pulmonology", "audience": "U.S. physicians and medical trainees", "tags": [ "interstitial lung disease", "fibrotic ILD", "high-resolution CT", "usual interstitial pneumonia", "idiopathic pulmonary fibrosis", "progressive pulmonary fibrosis", "hypersensitivity pneumonitis", "CTD-ILD" ], "keyTakeaways": [ "Obtain high-resolution chest CT and pulmonary function testing early; HRCT pattern recognition determines whether UIP/IPF is likely and whether tissue sampling may add value. [6][8][17]", "Do not label ILD idiopathic before systematically assessing medication exposure, occupational or environmental antigens, and connective-tissue disease features; chronic hypersensitivity pneumonitis and CTD-ILD can mimic UIP-pattern disease. [7][19]", "A radiologic UIP pattern with no alternative clinical explanation can support IPF after multidisciplinary review; uncertain clinical-radiologic cases may require lung biopsy consideration. [6][7][8]", "Track symptoms, FVC, DLCO, and serial HRCT when clinically indicated; progressive pulmonary fibrosis is identified by worsening across these domains over follow-up. [5][9]", "For confirmed IPF, antifibrotic therapy with pirfenidone or nintedanib is initial disease-modifying treatment, alongside pulmonary rehabilitation, smoking cessation, oxygen when needed, and early transplant or palliative-care consideration. [6]" ], "sections": [ { "id": "triage-and-baseline-assessment", "eyebrow": "Initial assessment", "heading": "Establish whether the presentation is acute, chronic, or acutely worsened", "intro": "Separate a new diffuse lung process from progression of established fibrotic disease before assigning an ILD subtype.", "paragraphs": [ "In a patient with new or worsening dyspnea, cough, hypoxemia, or diffuse parenchymal abnormalities, first determine whether the clinical tempo is acute, subacute, or chronic and compare with prior chest imaging, HRCT, spirometry, lung volumes, and DLCO. A restrictive physiology or reduced DLCO supports physiologic impairment but does not establish a specific ILD diagnosis; HRCT is the pivotal imaging study for defining the diffuse parenchymal pattern. [12][14]", "Treat acute deterioration in a patient with established fibrotic ILD as a separate diagnostic event rather than automatically as fibrosis progression. Acute exacerbations in rheumatoid arthritis-associated ILD have been associated with very high mortality, and acute worsening plus FVC decline are mortality-associated events in IPF. Obtain an updated HRCT and reassess competing causes of deterioration before attributing decline to the underlying ILD alone. [21][22]", "Document resting and exertional oxygen requirement, symptom trajectory, smoking history, medication chronology, prior thoracic irradiation or inhalational exposures, occupational exposures, home antigen exposures, and systemic autoimmune features. This history determines whether the leading branch is exposure-associated ILD, CTD-ILD, medication-related disease, or an idiopathic interstitial pneumonia; chronic hypersensitivity pneumonitis is a key alternative diagnosis in a fibrotic presentation. [7][19]" ], "bullets": [ "Obtain HRCT rather than relying on chest radiography to characterize a suspected interstitial pattern. [12]", "Obtain baseline spirometry, lung volumes, and DLCO for physiologic staging and later trend assessment. [13][14]", "Refer diagnostically difficult, progressive, or biopsy-considered cases for ILD multidisciplinary discussion integrating clinical, radiologic, and pathologic data. [6][7][13][16]" ], "subsections": [], "table": { "caption": "Initial branches in suspected fibrotic ILD. [6][7][19]", "columns": [ "Clinical-imaging branch", "Discriminator to obtain", "Immediate diagnostic consequence" ], "rows": [ [ "Probable IPF/UIP-spectrum disease", "HRCT categorized as UIP, probable UIP, indeterminate for UIP, or alternative diagnosis; exclude another clinical cause. [6][8]", "Submit clinical and HRCT findings to multidisciplinary review; a radiologic UIP pattern may establish IPF without surgical biopsy when no alternative process is identified. [6][7]" ], [ "Exposure-associated fibrotic ILD", "Focused environmental, occupational, and antigen exposure history; evaluate HRCT for features that change the differential toward hypersensitivity pneumonitis. [7][17][19]", "Prioritize exposure identification and avoidance; do not assume UIP-pattern fibrosis is idiopathic. [7][19]" ], [ "Connective-tissue disease-associated ILD", "Review systemic manifestations and directed autoimmune testing in conjunction with HRCT and pulmonary physiology. [5][13]", "Coordinate pulmonary and rheumatologic classification because disease behavior and treatment strategy differ from IPF. [5][13]" ], [ "Unclassifiable or discordant ILD", "Identify discordance among clinical history, HRCT, and physiology after expert review. [6][8][16]", "Consider whether histopathology would change diagnosis or management before pursuing surgical biopsy or transbronchial cryobiopsy. [6][8][16]" ] ] } }, { "id": "hrct-pattern-directed-diagnosis", "eyebrow": "Imaging branch point", "heading": "Use HRCT pattern to narrow the diagnosis and decide on tissue sampling", "intro": "HRCT should be interpreted as a diagnostic pattern, not as a generic label of fibrosis.", "paragraphs": [ "Classify suspected IPF imaging using the four HRCT categories refined in the 2018 ATS/ERS/JRS/ALAT diagnostic framework: UIP, probable UIP, indeterminate for UIP, and alternative diagnosis. The category determines the confidence of IPF diagnosis and whether additional pathology is potentially informative. [8]", "A UIP-pattern distribution is typically basal-predominant, with reticulation and honeycombing increasing from apex to base; traction bronchiectasis and honeycombing also carry prognostic information in ILD. Conversely, air trapping and subpleural sparing are HRCT signs that can redirect the differential away from straightforward IPF toward alternative ILD patterns. [17][24]", "When the clinical context contains no alternative cause and HRCT demonstrates UIP, IPF can usually be confirmed through multidisciplinary review without surgical lung biopsy. Histopathology should be considered when clinical and radiologic data leave meaningful diagnostic uncertainty and when a tissue result would alter management. [6][7]" ], "bullets": [ "Request expert thoracic-radiology review of HRCT when the report does not assign a recognized ILD pattern or when exposure history and CT interpretation conflict. [8][16][17]", "Do not treat probable UIP as an automatic mandate for surgery: ATS/ERS/JRS/ALAT guidance conditionally supported surgical lung biopsy in selected patients, whereas Fleischner guidance recommended against routine biopsy in newly detected IIP with probable UIP. [8]", "Use tissue sampling selectively after multidisciplinary discussion; cryobiopsy protocols have lacked standardized specifications for size, number, and sampling locations. [16]" ], "subsections": [ { "heading": "Pathology and multidisciplinary review", "paragraphs": [ "The value of surgical lung biopsy or transbronchial cryobiopsy is highest when the pretest differential remains consequential after HRCT and clinical evaluation—for example, when distinguishing IPF/UIP from chronic hypersensitivity pneumonitis or another fibrotic ILD would change therapeutic direction. Histologic UIP must be interpreted with exposure and autoimmune context because UIP is a pattern, not synonymous with idiopathic disease. [7][19]" ], "bullets": [ "Avoid biopsy when the expected result is unlikely to alter diagnosis or management after expert clinical-radiologic review. [6][7]", "Include pulmonology, thoracic radiology, and pathology in multidisciplinary diagnosis when available; this approach is central to IPF confirmation without biopsy and to resolving complex ILD classification. [6][7][13][16]" ] } ], "table": { "caption": "HRCT features that alter the fibrotic ILD differential. [8][17]", "columns": [ "HRCT feature", "Interpretation", "Diagnostic action" ], "rows": [ [ "Basal-predominant reticulation and honeycombing", "Supports a UIP-pattern fibrotic process when paired with compatible distribution and clinical context. [17]", "Classify within the UIP/probable UIP/indeterminate/alternative-diagnosis framework and review for secondary causes before diagnosing IPF. [8]" ], [ "Traction bronchiectasis", "Supports fibrotic architectural distortion and contributes to radiologic severity assessment. [17][24]", "Compare extent on serial HRCT with prior studies when progression is suspected. [24]" ], [ "Air trapping", "Can narrow the differential toward diagnoses other than straightforward IPF/UIP. [17]", "Revisit exposure history and assess for chronic hypersensitivity pneumonitis in multidisciplinary review. [7][19]" ], [ "Subpleural sparing", "Can exclude or reduce the likelihood of some UIP-pattern diagnostic possibilities. [17]", "Do not assign IPF solely from fibrosis; pursue alternative-pattern interpretation. [8][17]" ] ] } }, { "id": "etiologic-branches", "eyebrow": "Cause-directed classification", "heading": "Distinguish idiopathic, exposure-related, and autoimmune fibrotic ILD", "intro": "Etiology changes both treatment selection and the meaning of a UIP pattern.", "paragraphs": [ "Diagnose IPF only after excluding an alternative disease process. IPF is a chronic progressive fibrosing interstitial pneumonia of unknown etiology defined by radiologic and/or histopathologic UIP; in the appropriate clinical setting, multidisciplinary review of HRCT can establish the diagnosis without biopsy. [6][7]", "For suspected hypersensitivity pneumonitis, make a structured antigen and exposure assessment central to the workup, then integrate the exposure history with HRCT and, when needed, pathology. Chronic hypersensitivity pneumonitis is an important pathologic and clinical mimic of IPF/UIP, so an apparent UIP pattern does not end the exposure evaluation. [7][19]", "For possible CTD-ILD, use systemic history, examination, directed autoimmune evaluation, HRCT pattern, and pulmonary physiology together rather than relying on a single serologic result. In Sjögren syndrome-associated ILD, UIP pattern was more frequent among patients meeting progressive pulmonary fibrosis criteria than among nonprogressors in one cohort, illustrating that a UIP pattern can occur in autoimmune ILD and may identify higher-risk disease behavior. [5]" ], "bullets": [ "Classify the patient as IPF only when no medication, exposure, autoimmune, or other clinical explanation better accounts for the fibrotic ILD. [6][7]", "If autoimmune disease or an exposure is plausible, preserve that etiologic diagnosis even when HRCT or pathology shows UIP-pattern fibrosis. [5][7][19]", "Use longitudinal behavior in addition to baseline diagnosis: UIP radiologic pattern is associated with worse prognosis across ILD subtypes. [2]" ], "subsections": [], "table": { "caption": "Etiologic classification determines the next management conversation. [5][6][7][19]", "columns": [ "Working diagnosis", "Evidence that supports it", "Decision consequence" ], "rows": [ [ "Idiopathic pulmonary fibrosis", "No alternative disease process plus radiologic and/or histopathologic UIP; multidisciplinary confirmation is usual. [6][7]", "Initiate an IPF-specific antifibrotic discussion and assess supportive, transplant, and palliative-care needs early. [6]" ], [ "Chronic hypersensitivity pneumonitis", "Relevant exposure history integrated with HRCT and, where needed, pathology. [7][19]", "Identify and eliminate the relevant antigen exposure and avoid misclassification as idiopathic disease. [19]" ], [ "CTD-ILD", "Connective-tissue disease context plus ILD identified through HRCT, pulmonary function testing, and multidisciplinary assessment. [5][13]", "Coordinate pulmonary-rheumatologic treatment and monitor for progressive pulmonary fibrosis. [5]" ], [ "Unclassifiable fibrotic ILD", "Persistent uncertainty after integrated clinical, radiologic, and pathologic review. [16]", "Follow symptoms, physiology, and imaging for a progressive phenotype and reconsider tissue only if it would change management. [9][16]" ] ] } }, { "id": "progression-monitoring", "eyebrow": "Longitudinal management", "heading": "Identify progressive pulmonary fibrosis with multidomain follow-up", "intro": "Progression is a longitudinal clinical-radiologic-physiologic determination rather than a single isolated test result.", "paragraphs": [ "At baseline, document symptoms, FVC, DLCO, and HRCT extent/pattern so that subsequent change can be judged against an interpretable reference. Across fibrotic ILDs other than IPF, progression occurs in an estimated 18% to 32% of patients; IPF is intrinsically progressive over time. [9]", "Use serial symptoms, pulmonary function, and imaging together. The ATS progressive pulmonary fibrosis framework applied in Sjögren-associated ILD defines progression within 1 year by at least two of three domains: worsening symptoms, physiologic decline, and radiologic progression. In that cohort, physiologic progression was FVC decline of at least 5% and/or DLCO decline of at least 10%. [5]", "Interpret FVC decline in clinical context. A decline of at least 10% in FVC and at least 15% in DLCO has also been used as a PFT progression definition in ILD research, illustrating that thresholds vary across studies and should not replace integrated review of symptoms and HRCT. [3][5][9]", "Escalate reassessment when symptoms worsen, FVC or DLCO falls, oxygen needs rise, or HRCT shows expanding fibrosis. In addition to confirming progression, search for superimposed triggers or alternate causes of deterioration before changing long-term ILD therapy. [5][21][22][24]" ], "bullets": [ "At each follow-up, compare current FVC and DLCO with prior values rather than relying on a single percent-predicted measurement. [3][5][9]", "Obtain interval HRCT when clinical or physiologic change creates uncertainty about radiologic progression or an alternate cause of worsening. [5][24]", "Treat a UIP radiologic pattern as a prognostic risk marker across ILD subtypes, not solely as an IPF diagnostic label. [2]" ], "subsections": [], "table": { "caption": "Practical progression framework for fibrotic ILD. [3][5][9]", "columns": [ "Follow-up domain", "Concerning change", "Next action" ], "rows": [ [ "Symptoms", "Worsening respiratory symptoms within 1 year. [5]", "Reassess oxygen requirement, compare physiology, and obtain imaging when the cause is not clear. [5][22]" ], [ "FVC", "At least 5% decline was used in the ATS-derived PPF framework; at least 10% decline is another research progression threshold. [3][5]", "Confirm trend, assess concurrent symptoms and HRCT, and determine whether progression criteria are met. [5][9]" ], [ "DLCO", "At least 10% decline was used in the ATS-derived PPF framework; at least 15% decline is another research progression threshold. [3][5]", "Interpret with imaging and clinical status rather than as an isolated progression diagnosis. [5][9]" ], [ "HRCT", "Radiologic progression paired with worsening symptoms or functional decline supports PPF within 1 year. [5]", "Review images longitudinally with thoracic radiology and reconsider disease classification or treatment strategy. [5][24]" ] ] } }, { "id": "ipf-treatment-and-support", "eyebrow": "Confirmed IPF", "heading": "Start disease-modifying and supportive management without delaying advanced-care planning", "intro": "Treatment in IPF combines antifibrotic therapy with symptom-directed and advanced-care interventions.", "paragraphs": [ "For confirmed IPF, initial disease-modifying therapy is an antifibrotic agent: pirfenidone or nintedanib. Choice should be individualized through discussion of adverse-effect tolerance, comorbidities, drug interactions, treatment burden, and patient goals; the diagnostic label should be secure because IPF-directed therapy follows exclusion of alternative fibrotic ILD causes. [6]", "Nerandomilast, an oral phosphodiesterase-4 inhibitor, is an FDA-approved IPF treatment and reduced FVC decline versus placebo over 1 year in a randomized phase 3 trial. Incorporate it through an IPF-specific medication review, with selection and monitoring based on current prescribing information and patient-specific factors. [6]", "Prescribe smoking cessation support, pulmonary rehabilitation, and supplemental oxygen when indicated as parallel management rather than as substitutes for antifibrotic treatment. Discuss lung-transplant referral and palliative-care involvement early, including for patients receiving active disease-modifying therapy. [6]" ], "bullets": [ "Confirm IPF through multidisciplinary clinical-radiologic assessment before initiating an IPF-specific treatment pathway. [6][7]", "Monitor FVC, DLCO, symptoms, exercise-related oxygen needs, and HRCT when change in disease behavior is suspected. [5][9]", "Revisit transplant eligibility and goals-of-care planning with clinically meaningful decline, increasing oxygen needs, or progressive fibrotic disease despite treatment. [6]" ], "subsections": [], "table": { "caption": "Core management elements after IPF confirmation. [6]", "columns": [ "Management domain", "Action", "Clinical purpose" ], "rows": [ [ "Antifibrotic therapy", "Offer pirfenidone or nintedanib as initial therapy. [6]", "Disease-modifying treatment for IPF. [6]" ], [ "Newer pharmacotherapy", "Consider FDA-approved oral nerandomilast within an IPF medication plan. [6]", "A phase 3 trial showed less FVC decline than placebo at 1 year. [6]" ], [ "Functional support", "Implement smoking cessation, pulmonary rehabilitation, and supplemental oxygen when indicated. [6]", "Address modifiable risk, exercise limitation, and hypoxemia. [6]" ], [ "Advanced care", "Discuss early lung-transplant referral and palliative-care options. [6]", "Plan for progressive disease while active treatment continues. [6]" ] ] } } ], "faq": [ { "question": "When is lung biopsy appropriate in suspected IPF?", "answer": "Consider surgical biopsy when clinical and HRCT findings remain diagnostically uncertain and pathology would change management. UIP-pattern HRCT with no alternative cause can support IPF without biopsy after multidisciplinary review; probable UIP is an area of guideline disagreement and should be individualized. [6][7][8]" }, { "question": "Can a UIP pattern establish idiopathic pulmonary fibrosis in a patient with autoimmune disease or exposure history?", "answer": "No. UIP is a radiologic and histopathologic pattern that can occur in chronic hypersensitivity pneumonitis and CTD-ILD. Establish IPF only after alternative etiologies are excluded through exposure, medication, autoimmune, imaging, and multidisciplinary assessment. [5][6][7][19]" } ], "references": [ { "number": 1, "title": "from childhood to adult interstitial lung disease", "detail": "thorax.bmj.com", "url": "https://thorax.bmj.com/content/79/12/1162", "authors": "thorax.bmj.com", "host": "thorax.bmj.com" }, { "number": 2, "title": "Associations of interstitial lung disease subtype and CT ...", "detail": "thorax.bmj.com", "url": "https://thorax.bmj.com/content/80/12/927", "authors": "thorax.bmj.com", "host": "thorax.bmj.com" }, { "number": 3, "title": "AB0829 PROGRESSION OF ILD (INTERSTITIAL LUNG ...", "detail": "ard.bmj.com", "url": "https://ard.bmj.com/content/82/Suppl_1/1627.2", "authors": "ard.bmj.com", "host": "ard.bmj.com" }, { "number": 4, "title": "BTS Clinical Statement on pulmonary sarcoidosis", "detail": "thorax.bmj.com", "url": "https://thorax.bmj.com/content/early/2020/12/02/thoraxjnl-2019-214348?versioned=true", "authors": "thorax.bmj.com", "host": "thorax.bmj.com" }, { "number": 5, "title": "POS1453 PROGRESSIVE PULMONARY FIBROSIS ACCORDING TO THE NEW ATS DEFINITION IS NOT UNCOMMON IN THE CONTEXT OF SJÖGREN’S SYNDROME-ASSOCIATED INTERSTITIAL LUNG DISEASE | Annals of the Rheumatic Diseases", "detail": "ard.bmj.com", "url": "https://ard.bmj.com/content/82/Suppl_1/1080.1", "authors": "ard.bmj.com", "host": "ard.bmj.com" }, { "number": 6, "title": "Idiopathic pulmonary fibrosis - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/446", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 7, "title": "The histologic diagnosis of usual interstitial pneumonia of idiopathic pulmonary fibrosis. Where we are and where we need to go | Modern Pathology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41379-021-00889-5", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 8, "title": "Diagnostic and prognostic implications of 2018 guideline for the diagnosis of idiopathic pulmonary fibrosis in clinical practice | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-021-95728-7", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 9, "title": "Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-025-22483-4", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 10, "title": "Interstitial lung disease diagnosis and prognosis using an ...", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-023-37720-5", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 11, "title": "Immune mechanisms in fibrotic interstitial lung disease", "detail": "www.cell.com", "url": "https://www.cell.com/cell/fulltext/S0092-8674(24)00524-5", "authors": "www.cell.com", "host": "www.cell.com" }, { "number": 12, "title": "Basic HRCT patterns in diffuse interstitial lung disease", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S2173510722001409", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 13, "title": "APSR 2024 Abstracts - 2024 - Respirology", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/resp.14835", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 14, "title": "Correlation of high resolution CT patterns with pulmonary ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0422763815301448", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 15, "title": "APSR 2025 - 2025 - Respirology - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1002/resp.70142", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 16, "title": "The interstitial lung disease multidisciplinary meeting", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.13163", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 17, "title": "Radiographic Signs and Patterns in Interstitial Lung Disease", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0037198X18300981", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 18, "title": "Assessment and Management of Occupational ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2213219820309399", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 19, "title": "Diagnosis and management of hypersensitivity ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/resp.14847", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 20, "title": "Syndrome of Combined Pulmonary Fibrosis and Emphysema", "detail": "academic.oup.com", "url": "https://academic.oup.com/ajrccm/article/206/4/e7/8491809", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 21, "title": "Interstitial Lung Disease in Antineutrophil Cytoplasmic ...", "detail": "acrjournals.onlinelibrary.wiley.com", "url": "https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70078", "authors": "acrjournals.onlinelibrary.wiley.com", "host": "acrjournals.onlinelibrary.wiley.com" }, { "number": 22, "title": "Clinical Course of Interstitial Lung Disease in Patients With ...", "detail": "acrjournals.onlinelibrary.wiley.com", "url": "https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.11736", "authors": "acrjournals.onlinelibrary.wiley.com", "host": "acrjournals.onlinelibrary.wiley.com" }, { "number": 23, "title": "Inter‐Organ Communication in Pulmonary Fibrosis: Systemic ...", "detail": "faseb.onlinelibrary.wiley.com", "url": "https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.202603126", "authors": "faseb.onlinelibrary.wiley.com", "host": "faseb.onlinelibrary.wiley.com" }, { "number": 24, "title": "CT Honeycombing and Traction Bronchiectasis Extent ...", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/pdf/10.1148/radiol.241001", "authors": "pubs.rsna.org", "host": "pubs.rsna.org" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "from childhood to adult interstitial lung disease", "detail": "thorax.bmj.com", "url": "https://thorax.bmj.com/content/79/12/1162", "authors": "thorax.bmj.com", "host": "thorax.bmj.com", "snippet": "by M Griese · 2024 · Cited by 21 — Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ats/ers/jrs/alat clinical practice guideline. Am J", "score": 0.7125728 }, { "number": 2, "title": "Associations of interstitial lung disease subtype and CT ...", "detail": "thorax.bmj.com", "url": "https://thorax.bmj.com/content/80/12/927", "authors": "thorax.bmj.com", "host": "thorax.bmj.com", "snippet": "by JS Kim · 2025 · Cited by 20 — Patients with a usual interstitial pneumonia (UIP) radiological pattern have a worse prognosis across different types of interstitial lung diseases (ILDs).", "score": 0.23173632 }, { "number": 3, "title": "AB0829 PROGRESSION OF ILD (INTERSTITIAL LUNG ...", "detail": "ard.bmj.com", "url": "https://ard.bmj.com/content/82/Suppl_1/1627.2", "authors": "ard.bmj.com", "host": "ard.bmj.com", "snippet": "Progression of ILD was defined in PFT as: decline ≥ 10% in FVC ≥ 15% in DLCO. Progression of ILD in HRCT was considered according to radiologists'criteria.", "score": 0.45391592 }, { "number": 4, "title": "BTS Clinical Statement on pulmonary sarcoidosis", "detail": "thorax.bmj.com", "url": "https://thorax.bmj.com/content/early/2020/12/02/thoraxjnl-2019-214348?versioned=true", "authors": "thorax.bmj.com", "host": "thorax.bmj.com", "snippet": "Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One 2014;9:e86716. doi:10.1371/journal.pone", "score": 0.41506538 }, { "number": 5, "title": "POS1453 PROGRESSIVE PULMONARY FIBROSIS ACCORDING TO THE NEW ATS DEFINITION IS NOT UNCOMMON IN THE CONTEXT OF SJÖGREN’S SYNDROME-ASSOCIATED INTERSTITIAL LUNG DISEASE | Annals of the Rheumatic Diseases", "detail": "ard.bmj.com", "url": "https://ard.bmj.com/content/82/Suppl_1/1080.1", "authors": "ard.bmj.com", "host": "ard.bmj.com", "snippet": "Out of 46 SS-ILD patients with available follow-up data: 13/46 (28.3%) presented worsening clinical symptoms; 13/42 (31%) experimented significant decline of FVC (≥5%) and/or DLCO (≥10%), while 4 patients were unable to perform PFT due to desaturation; 3/46 (6.5%) patients died because of ILD progre", "score": 0.3135884 }, { "number": 6, "title": "Idiopathic pulmonary fibrosis - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/446", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "In the absence of findings suggesting an alternative disease process, IPF is usually confirmed by multidisciplinary review based on the presence of a radiologic (high-resolution chest CT) pattern of usual interstitial pneumonia (UIP).\n\nHistopathology of lung biopsy samples may be considered when rad", "score": 0.6227582 }, { "number": 7, "title": "The histologic diagnosis of usual interstitial pneumonia of idiopathic pulmonary fibrosis. Where we are and where we need to go | Modern Pathology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41379-021-00889-5", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \n Google Scholar\n6. Raghu, G. et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 198, e44–e68 (2018).\n\n Article \n Google Scholar\n7. Raghu, G. et al. Diagnosis of hypersensitivity pneumonitis in adu", "score": 0.7511561 }, { "number": 8, "title": "Diagnostic and prognostic implications of 2018 guideline for the diagnosis of idiopathic pulmonary fibrosis in clinical practice | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-021-95728-7", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \n Google Scholar\n22. Travis, W. D. et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188, 733–748 (2013).\n\n Article ", "score": 0.70750624 }, { "number": 9, "title": "Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease | Scientific Reports", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-025-22483-4", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \n PubMed \n PubMed Central \n Google Scholar\n14. Raghu, G. et al. Diagnosis of idiopathic pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir Crit. Care Med. 198 (5), e44–e68 (2018).\n\n Article \n PubMed \n Google Scholar\n15. Standardized ", "score": 0.6369636 }, { "number": 10, "title": "Interstitial lung disease diagnosis and prognosis using an ...", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41467-023-37720-5", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "by X Mei · 2023 · Cited by 110 — ... hypersensitivity pneumonitis (CHP), 142 patients (31.6%) with NSIP ... An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis:", "score": 0.6369636 }, { "number": 11, "title": "Immune mechanisms in fibrotic interstitial lung disease", "detail": "www.cell.com", "url": "https://www.cell.com/cell/fulltext/S0092-8674(24)00524-5", "authors": "www.cell.com", "host": "www.cell.com", "snippet": "by M Kamiya · 2024 · Cited by 124 — Fibrotic interstitial lung diseases (fILDs) have poor survival rates and lack effective therapies. Despite evidence for immune mechanisms in", "score": 0.28317937 }, { "number": 12, "title": "Basic HRCT patterns in diffuse interstitial lung disease", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S2173510722001409", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "by AG Palleiro · 2022 · Cited by 14 — It is important to note that HRCT should always confirm the detection of an interstitial pattern on a chest radiograph. ... pulmonary function tests and", "score": 0.6617704 }, { "number": 13, "title": "APSR 2024 Abstracts - 2024 - Respirology", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/resp.14835", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Discussion: Interstitial lung disease diagnosis is complex and requires various tests and procedures. The patient underwent routine tests, including pulmonary function tests, chest x-rays, and CT scans.1 Treatment options include medications to reduce inflammation, tyrosine kinase inhibitor, oxygen ", "score": 0.5852203 }, { "number": 14, "title": "Correlation of high resolution CT patterns with pulmonary ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0422763815301448", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "by K Hussein · 2016 · Cited by 19 — HRCT patterns and the degree of lung involvement of ILDs correlate with pulmonary function parameters. Lung volumes are lower in fibrotic lesion regardless", "score": 0.5820878 }, { "number": 15, "title": "APSR 2025 - 2025 - Respirology - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1002/resp.70142", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Results: 39 patients with 67% being biopsy-proven (mean age 49.8 ±14.65 years, 77% male, 93% had a smoking history) with a median follow-up duration of 27 months (range 17.5–51). Baseline PFT values showed FEV1 at 82.8 ± 15.6% predicted and FVC at 86.1 ± 14.9% predicted, with the patterns observed i", "score": 0.57035583 }, { "number": 16, "title": "The interstitial lung disease multidisciplinary meeting", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.13163", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "by JD Prasad · 2017 · Cited by 73 — The role of bronchoscopic lung cryobiopsy is evolving, and at this stage protocols are lacking defining the size, number and sampling locations to achieve the", "score": 0.5513086 }, { "number": 17, "title": "Radiographic Signs and Patterns in Interstitial Lung Disease", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0037198X18300981", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "## Conclusion\n\nThe diagnosis of diffuse lung disease is aided by the recognition of patterns on HRCT and radiographic signs when present help indicate specific ILD diagnosis. The evidence associated with each of these signs differs. In some cases, such as honeycombing, air trapping or subpleural spa", "score": 0.5134007 }, { "number": 18, "title": "Assessment and Management of Occupational ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2213219820309399", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Use of transbronchial cryobiopsy in the diagnosis of interstitial lung disease—a systematic review and cost analysis. QJM, 110 (2017), pp", "score": 0.44275752 }, { "number": 19, "title": "Diagnosis and management of hypersensitivity ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/resp.14847", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "by H Barnes · 2024 · Cited by 10 — Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study.", "score": 0.3825571 }, { "number": 20, "title": "Syndrome of Combined Pulmonary Fibrosis and Emphysema", "detail": "academic.oup.com", "url": "https://academic.oup.com/ajrccm/article/206/4/e7/8491809", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "by V Cottin · 2022 · Cited by 242 — Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised", "score": 0.61363083 }, { "number": 21, "title": "Interstitial Lung Disease in Antineutrophil Cytoplasmic ...", "detail": "acrjournals.onlinelibrary.wiley.com", "url": "https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70078", "authors": "acrjournals.onlinelibrary.wiley.com", "host": "acrjournals.onlinelibrary.wiley.com", "snippet": "by A Chalkia · Cited by 3 — Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac", "score": 0.6208291 }, { "number": 22, "title": "Clinical Course of Interstitial Lung Disease in Patients With ...", "detail": "acrjournals.onlinelibrary.wiley.com", "url": "https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr2.11736", "authors": "acrjournals.onlinelibrary.wiley.com", "host": "acrjournals.onlinelibrary.wiley.com", "snippet": "by EL Matteson · 2024 · Cited by 11 — Acute worsenings of RA-ILD, known as acute exacerbations, are associated with very high mortality. A retrospective study of 149", "score": 0.60694176 }, { "number": 23, "title": "Inter‐Organ Communication in Pulmonary Fibrosis: Systemic ...", "detail": "faseb.onlinelibrary.wiley.com", "url": "https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.202603126", "authors": "faseb.onlinelibrary.wiley.com", "host": "faseb.onlinelibrary.wiley.com", "snippet": "Pulmonary fibrosis (PF) is a chronic, progressive interstitial lung disease characterized by recurrent alveolar epithelial injury,", "score": 0.37524903 }, { "number": 24, "title": "CT Honeycombing and Traction Bronchiectasis Extent ...", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/pdf/10.1148/radiol.241001", "authors": "pubs.rsna.org", "host": "pubs.rsna.org", "snippet": "by DC Marinescu · 2025 · Cited by 26 — Prognostic value of radiologic features in interstitial lung disease (ILD) has been predominantly studied in idiopathic pulmonary fibrosis, but", "score": 0.3440251 } ], "publishedAt": "2026-08-24T18:20:09.393719+00:00", "updatedAt": "2026-08-24T18:20:09.393719+00:00", "readingMinutes": 6, "slug": "interstitial-lung-disease" }